东森

Be the most trusted biotech company

2025-02-12

Phase 3 MRCT Results of Denosumab Biosimilar HLX14 Released at ORS 2025
2025-02-10

First Subject Dosed for a Phase 2 Clinical Trial of Henlius’ PD-L1-Targeting ADC HLX43
2025-02-06

Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
2025-02-05

Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
2025-02-02

US FDA Accepts Biologics License Application (BLA) for HLX11, Biosimilar Candidate of Perjeta® (pertuzumab)
2025-01-26

Results from Clinical Trials of Two Henlius’ Innovative Products Released at ASCO GI 2025
2025-01-24

Serplulimab plus HLX04 for HCC: Phase 2 Results Published in Cancer Immunology, Immunotherapy
2025-01-13

Henlius Broadens Access to Multiple Biologics in Emerging Markets
2025-01-09

Henlius to Present Latest Clinical Data of HLX10 and HLX22 at 2025 ASCO GI

1
2
3
4
5